Acinar Cell Carcinoma, Advanced Cancer, Endometrial Cancer, Fallopian Tube Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Primary Peritoneal Cancer
Conditions
Keywords
Loss of Ataxia Telangiectasia Mutated (ATM) protein
Brief summary
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Detailed description
ART0380 is a new investigational medicinal product that is a potent and selective inhibitor of Ataxia telangiectasia and Rad3-related (ATR). ART0380 is being developed as an oral anti-cancer agent for the treatment of participants with cancers that harbor defects in deoxyribonucleic acid (DNA) repair and in combination with agents including those that cause DNA damage. This study is an open-label Phase I/IIa study designed to evaluate the safety, tolerability, PK and preliminary efficacy of ART0380 as monotherapy or in combination with gemcitabine or irinotecan in participants with advanced or metastatic solid tumors, advanced or solid tumors that fail to express Ataxia-Telangiectasia Mutated protein kinase (ATM), and high grade serous ovarian, primary peritoneal or fallopian tube carcinoma.
Interventions
DRUGART0380
Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.
DRUGGemcitabine
Gemcitabine will be administered on Days 1 and 8 of a 21-day cycle.
DRUGIrinotecan
Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.
Sponsors
Artios Pharma Ltd
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
General Inclusion Criteria: * Signed informed consent * Discontinued all previous treatments for cancer for at least 21 days or 5 half-lives, whichever is shorter, and recovered from the acute effects of therapy to CTCAE Grade ≤1. Palliative radiotherapy must have completed 1 week prior to start of study treatment. * If patients have a known germline BRCA mutation or a cancer with a somatic BRCA mutations or which is HRD positive and for which there is an approved PARP inhibitor, participants should have received such treatment before participating in the study unless contra-indicated * At least 1 radiologically evaluable lesion (measurable and/or non-measurable) that can be assessed at baseline and is suitable for repeated radiological evaluation by RECIST v1.1 or Prostate Cancer Working Group-3 Guidelines (PCWG-3) * Acceptable hematologic, renal, hepatic, and coagulation functions independent of transfusions and granulocyte colony-stimulating factor * Non-irradiated tumor tissue sample (archival or newly obtained core biopsy of a tumor lesion) available for submission for analysis. * Female patients of childbearing potential and male patients with female partners of childbearing potential are required to use highly effective contraception plus one barrier method during their participation in the study and for 7 months and 5 months respectively following the last dose. For male and female patients given gemcitabine or irinotecan, highly effective contraception plus one barrier method must be used from study entry until 6 months after the last dose of study treatment. Male patients are required to refrain from donating sperm and female patients are required to refrain from donating eggs, during their participation in the study and for 6 months following last dose. * Estimated life expectancy of ≥12 weeks * Reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures * Performance status of 0-1 on the ECOG Scale Additional inclusion criteria for participants in dose escalation (Part A1): * Advanced or metastatic cancer which is refractory to standard therapies, or for which no standard therapies exist, or for which the investigator feels no other active therapy is required for the duration of the study * Performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale Additional inclusion criteria for participants in dose escalation (Part A2): •Advanced or metastatic cancer for which gemcitabine is an appropriate treatment. Prior treatment with gemcitabine is permitted. Additional inclusion criteria for participants in dose escalation (Part A3): * Advanced or metastatic cancer for which irinotecan is an appropriate treatment. Prior treatment with irinotecan is permitted. * For food effect cohort only: Patients must be able to eat a high-fat meal within a 30 minute period, as provided by the study site. Additional inclusion criteria for participants in dose expansion (Part B1): * Patients with advanced or metastatic solid tumors with alterations to the ATM gene likely to predict for loss of ATM protein * Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1 * For France only ART0380 Monotherapy; Patient that is not eligible for curative treatment, for whom all standard of care therapies have failed and no therapies known to provide clinical benefit are available. * Combination arms; Patients for which irinotecan is an appropriate treatment. Prior treatment with irinotecan is permitted. * For Spain only ART0380 Combination therapy, Patient that is not eligible for curative treatment, for whom standard of care therapies have failed. Additional inclusion criteria for participants in dose expansion (Part B2): * Patients with a known germline BRCA mutation, or a cancer with a known somatic BRCA mutation, or which is known to be HRD positive, and for which there is an approved PARP inhibitor should have received such treatment before participating in the study, unless contra-indicated. * Females with histologically-confirmed diagnosis of high grade serous carcinoma of the ovary, fallopian tube or primary peritoneum that is not amenable to curative therapy * Platinum-resistant disease. Patients must not have had primary platinum-refractory disease (disease that progressed during first-line platinum-based therapy). * No more than one prior regimen in the platinum-resistant setting. Hormonal therapies and antiangiogenic therapies (as single agents) and PARP inhibitors used as maintenance therapy are not considered as separate lines of therapy. Patients should have previously received bevacizumab and chemotherapy unless contra-indicated. * Have not received prior treatment with gemcitabine unless administered in combination with a platinum with no disease progression within 12 months after completion of that regimen * Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1 Inclusion criteria specific to Part B3 * Persistent or recurrent endometrial cancer with biological selection.: * Patients should have received taxane/platinum chemotherapy, unless contraindicated. * Measurable disease. Inclusion criteria specific to Part B4 * Advanced or metastatic solid cancers of any histology with biological selection * If a PD-1/PDL-1 inhibitor (eg, pembrolizumab) is approved and available for the patient's cancer, the patient should have received such treatment before participating in this study. * Radiologically evaluable disease * Performance status of 0-1 on the ECOG scale Inclusion criteria specific to Part B5 * Metastatic CRC with alterations to the ATM gene * Participants should have previously received appropriate prior lines of therapy in this setting. * Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1. * Patients have received a maximum of 2 prior chemotherapy regimens for the treatment of CRC. * Serum albumin ≥3g/dL within 7 days prior to first dose. * ECOG Performance Status must be stable for at least 2 weeks prior to enrollment. * Must have the clinical capacity to complete at least one 21-day treatment cycle without, in the investigator's judgment, a foreseeable need for prolonged hospitalization related to their underlying disease Inclusion criteria specific to Part B6: * Metastatic or locally advanced PDAC or acinar cell carcinoma with alterations to the ATM gene * Participants must have received at least 1 prior chemotherapy regimen for the treatment of the advanced disease OR have received neoadjuvant/adjuvant therapy with recurring occurring \<6 months following completion of this treatment. * Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1. Previously irradiated lesions may not be considered target lesions. * Serum albumin ≥3g/dL within 7 days prior to first dose. * ECOG Performance Status must be stable for at least 2 weeks prior to enrollment. * Must have the clinical capacity to complete at least one 21-day treatment cycle without, in the investigator's judgment, a foreseeable need for prolonged hospitalization related to their underlying disease. General
Exclusion criteria
* Women who are pregnant, breast feeding, or who plan to become pregnant while in the study or within 7 months after the last administration of study treatment * Men who plan to father a child while in the study or within5 months after the last administration of study treatment * Serious concomitant systemic disorder that would compromise the participants ability to adhere to the protocol including: one or more opportunistic HIV/AIDs-related infections within the past 12 months, a known hepatitis B virus, or known hepatitis C virus; documented active or chronic tuberculosis infection; malignancy prior to the one currently being treated that is not in remission * Have ongoing interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic). * Moderate or severe cardiovascular disease * Valvulopathy that is severe, moderate, or deemed clinically significant * Documented major electrocardiogram (ECG) abnormalities which are clinically significant * Symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment * Received a live vaccine within 30 days before the first dose of study treatment * History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate * Recent major surgery within 4 weeks prior to entry into the study or minor surgery within 1 week of entry into the study * Drainage for ascites, pleural effusion or pericardial fluid within 4 weeks before the first dose of study treatment. * A significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 12 weeks prior to enrollment * Currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities (DLTs) from ART0380 monotherapy and in combination with gemcitabine or irinotecan | From Cycle 0 Day -2 to Cycle 1 Day 21. Each cycle is 21 days. | — |
| Parts B1/B3/B4: Number of participants with adverse events following administration of ART0380 monotherapy and/or in combination with irinotecan at RP2Ds. | From Cycle 1 Day 1 until up to 30 days after the last dose of ART0380. Each cycle is 21 days. | Safety reported as incidence of adverse events |
| Part B2: Progression free survival by RECIST 1.1 in participants receiving ART0380 in combination with gemcitabine or gemcitabine alone | Every 6 weeks from Cycle 1 Day 1 for 18 weeks, then every 9 weeks up to approximately 24 months. Each cycle is 21 days. | Progression free survival (PFS) |
| Parts B5/B6: Object Response Rate (ORR) based on RECIST 1.1 to access anti-tumor activity of ART0380 in combination with irinotecan in each cohort. | Every 6 weeks from Cycle 1 Day 1, until disease progression or death or start of a new anti-cancer therapy, up to 2 years. Each Cycle is 21 days. | Objective Response Rate (ORR) |
Secondary
| Measure | Time frame |
|---|---|
| Part B2: Number of participants with adverse events following administration of ART0380 in combination with gemcitabine or gemcitabine alone | From Cycle 1 Day 1 until up to 30 days after the last dose of ART0380 or gemcitabine. Each cycle is 21 days. |
| Part B5/B6: Number of participants with adverse events following administration of ART0380 at the RP2D in combination with irinotecan. | From Cycle 1 Day 1 until up to 30 days after the last dose of ART0380 or irinotecan. Each cycle is 21 days. |
| Pharmacokinetic Analysis (single dose): determine the plasma concentration of ART0380 when given alone and in combination | PK will be measured at each cycle from Cycle 0 to Cycle 4. Each cycle is 21 days. |
| Pharmacokinetic Analysis (multiple dose): determine the plasma concentration of ART0380 when given alone and in combination | PK will be measured at each cycle from Cycle 0 to Cycle 4. Each cycle is 21 days. |
| Pharmacokinetic Analysis (single and multiple dose): Renal clearance of ART0380 | Urine PK will be measured during Cycle 1. Cycle 1 is 21 days. |
| Pharmacokinetic Analysis (single dose): Maximum plasma Concentration (Cmax) in a fasting and fed state. | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (single dose): Time to Maximum plasma concentration (Tmax) in a fasting and fed state | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (single dose): Terminal half-life (t1/2) in a fasting and fed state | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (single dose): Area Under the Curve Plasma Concentration Time Curve from zero to 24 hours (AUC0-24) in a fasting and fed state | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (single dose): Area Under The Curve Plasma Concentration Time Curve from zero to the time of last plasma concentration (AUC0-t) in a fasting and fed state | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (single dose): Area Under The Curve Plasma Concentration Time Curve from zero to 12 hours (AUC0-12) in a fasting and fed state. | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (single dose): Area under the concentration-time curve over the dosing interval (AUC(0-infinity)) in a fasting and fed state | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (single dose): Area under the concentration-time curve for Oral Clearance (CL/F) in a fasting and fed state | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (single dose): Area under the concentration-time curve for Volume of Distribution (Vz/F) in a fasting and fed state | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (multiple dose): Maximum plasma Concentration (Cmax ss) once steady sate has been reached. | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (multiple dose): Time to Maximum plasma concentration (Tmax ss) at steady state. | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (multiple dose): Time to lowest plasma concentration (Cmin ss) at steady state. | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (multiple dose): Terminal half-life (t1/2 ss) in a steady state. | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (multiple dose): Area Under The Curve Plasma Concentration Time Curve from zero to the time of last plasma concentration (AUC0-t ss) in a steady state. | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (multiple dose): Area Under The Curve Plasma Concentration Time Curve from zero to 12 hours (AUC0-12 ss) in a steady state. | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (multiple dose): Area Under the Curve Plasma Concentration Time Curve from zero to 24 hours (AUC0-24 ss) in a steady state. | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (multiple dose): Area Under the Curve Plasma Concentration Time (AUC ss) in a steady state. | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis (multiple dose): Area under the concentration-time curve for Oral Clearance (CL ss/F) in a steady state. | PK will be measured during Cycle 1. Cycle 1 is 21 days |
| Pharmacokinetic Analysis: The geometric mean ratio (GMR) and associated 90% confidence interval (Cl) for Area under the concentration-time curve over the dosing interval (AUC(0-infinity)) in a fasting and fed state. | PK will be measured during Cycle 1. Cycle 1 is 21 days. |
| Pharmacokinetic Analysis: The geometric mean ratio (GMR) and associated 90% confidence interval (Cl) for the maximum plasma concentration (Cmax) in a fasting and fed state. | PK will be measured during Cycle 1. Cycle 1 is 21 days. |
| Pharmacokinetic Parameters: Accumulation Rate (Rac) of increase in drug concentration in the body after repeated dosing compared to a single dose. | PK will be measured during Cycle 1. Cycle 1 is 21 days. |
| Pharmacokinetic Analysis: Urine concentration data following single and multiple oral dosing in monotherapy. | Urine PK will be measured during Cycle 1. Cycle 1 is 21 days. |
| Pharmacokinetic Analysis: Hodges-Lehmann estimate of median difference in tmax and associated 90% CI in a fasted and fed state. | PK will be measured during Cycle 1. Cycle 1 is 21 days. |
| Parts B1/B3/B4/B5/B6: Response and disease progression by Serological tumor markers (CA-19-9, CAE, CA-125, and Prostate Specific Antigen (PSA)). | Tumor markers will be measured for 18 weeks, then every 9 weeks thereafter. |
| Parts A1, A2, A3, B1, B3, B4: Objective response rate based on RECIST 1.1 | Every 6 weeks from Cycle 1 Day 1 for 18 weeks, then every 9 weeks up to approximately 24 months. Each cycle is 21 days. |
| Parts A1, A2, A3, B1, B3, B4, B5, and B6: Duration of response based on RECIST 1.1 | Every 6 weeks from Cycle 1 Day 1 for 18 weeks, then every 9 weeks up to approximately 24 months. Each cycle is 21 days. |
| Parts A1, A2, A3, B1, B3, B4, B5, and B6: Progression free survival based on RECIST 1.1 | Every 6 weeks from Cycle 1 Day 1 for 18 weeks, then every 9 weeks up to approximately 24 months. Each cycle is 21 days. |
| Parts B1/B3/B4/B5/B6: Overall Survival | After first dose through PFS/OS follow-up. |
Countries
France, Spain, United Kingdom, United States
Contacts
CONTACTSarah Cannon Development Innovations
STUDY_CHAIRMelissa Johnson, MD
Tennessee Oncology
STUDY_CHAIRAntonio Gonzalez, MD, PHD
Clinica Universidad de Navarra, Madrid
PRINCIPAL_INVESTIGATORSusanna Ulahannan, MD
Oklahoma University
PRINCIPAL_INVESTIGATORKim Reiss Binder, MD
University of Pennsylvania / Abramson Cancer Center
Outcome results
None listed